<DOC>
	<DOC>NCT00157534</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>The patient must be 18 to 65 years of age, inclusive. Primary diagnosis of chronic HCV infection. Patients who did not respond or relapsed following therapy with interferon.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Celgosivir</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
</DOC>